Comparative Effects of Sprint and Power Training in Cricket Fast Bowlers

July 15, 2024 updated by: Riphah International University

Comparative Effects of Sprint and Power Training on Speed and Repeated Sprint Ability in Cricket Fast Bowlers

Sprints can be a really effective way to improve participants cardiovascular fitness, strength and power, and running economy. Participants can gain bigger improvements and in less time with sprinting than with continuous easy running. Power training typically involves exercises which apply the maximum amount of force as fast as possible. Both these trainings are vital to increase the speed and repeated sprint ability in cricket fast bowlers.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Fast bowling requires a highly specialized and unique training approach as the whole body is used in the delivery of the ball to achieve maximum velocity. For this purpose, the fast bowlers must perform the sprint training which is high intensity interval training as it boosts the speed and power, helps to run faster, build muscles and increase the cardiovascular health. Along with sprint training fast bowlers undergo power training which also helps to run faster, improve strength and speed and maintain fitness.

It will be a Randomized clinical trial with sample size of 34 calculated by G-power with 10- m sprint test, using non probability convenient sampling technique. The study will include physically fit and healthy fast bowlers of age 18-30 years. Participants will be divided into 2 equal experimental groups. One group will perform sprint training which include 10 meter run or repeated sprint ability and other will perform power training including squat jump or countermovement jump consisting of 12 sessions for 4 weeks (3 sessions each week). Data will be assessed by using SPSS version 25

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
34

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Pakistan
    • Punjab
      • Zafarwal, Punjab, Pakistan, 51670
        • Recruiting
        • Zafarwal playzone
        • Contact:
        • Sub-Investigator:
          • Amna Shahid, T-DPT
        • Principal Investigator:
          • Ayesha Batool, MS-SPT

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Age: 18- 30 years
  2. Fast bowlers (male and female)
  3. Physically fit and healthy athletes
  4. Players must have fast bowling experience of at least 2 years. -

Exclusion Criteria:

  1. Fast bowlers with musculoskeletal conditions ( back pain, foot and ankle injuries, fracture of lower limb and bone deformity, patellar tendinopathy, ligamentous and meniscal injury)
  2. Vestibular and visual disorders
  3. cardiac and respiratory issues -

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: sprint training

group 1 will perform sprint training for 4 weeks, 3 sessions per week

Participants will perform 6 maximal 25-m sprint with recovery period of 25 seconds after each sprint for four weeks and three sessions per week.

Participants will perform 10 m sprint 2 trials with 2 minutes recovery period between each trial for four weeks and three sessions per week.

Participants will perform Vertical jump, 2 trials with 1-minute recovery period between each trial for four weeks, three sessions per week.
Other: sprint training
sprint training involves 20 meters sprint power training involve countermovement jump, squat jump and broad jump
Experimental: power training

GROUP 2 will perform POWER TRAINING for 4 weeks, 3 sessions per week Participants will perform Countermovement jump 2 trials, with 1-minute recovery between each trial for four weeks, three times per week.

Participants will perform squat jump 2 trials with 1-minute recovery between each trial for four weeks, three times per week.

Participants will perform broad jump 2 trials with 1-minute recovery between each trial for four weeks, three times per week.
Other: Power Training

GROUP 2 will perform POWER TRAINING for 4 weeks, 3 sessions per week Participants will perform Countermovement jump 2 trials, with 1-minute recovery between each trial for four weeks, three times per week.

Participants will perform squat jump 2 trials with 1-minute recovery between each trial for four weeks, three times per week.

Participants will perform broad jump 2 trials with 1-minute recovery between each trial for four weeks, three times per week.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Speed
Time Frame: 10 months
speed is assessed by 10-m sprint test. participants will run for 10 meters on the sound of GO. the time taken for the completion of 10 meter track will be recorded by a handled stopwatch. Measurements will be taken before and after 10-m sprint test.
10 months
Repeated Sprint Ability
Time Frame: 10 months
Repeated-sprint ability (RSA) is now well accepted as an important fitness component in team-sport performance. It is broadly described as the ability to perform repeated short (~3-4 s, 20-30 m) sprints with only brief (~10-30 s) recovery between bouts. measurements will be taken before and after the repeated sprint ability test.
10 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Riphah International University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Amna Shahid, t-DPT, Riphah International University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 15, 2023

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 15, 2024

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 25, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 11, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 15, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 19, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 19, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 15, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • REC/RCR &AHS/23/0476

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings